AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer

AnaptysBio Appoints Dr. Matthew Moyle As Chief Scientific Officer

Date
April 19, 2016
Location
SAN DIEGO, California

AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced the appointment of Matthew Moyle, Ph.D. as Chief Scientific Officer. Dr. Moyle will be responsible for the discovery and early development of therapeutic antibodies generated using AnaptysBio’s proprietary SHM-XEL platform.